Novavax (NVAX) Revenue (2010 - 2026)

Novavax's Revenue history runs 17 years deep, the most recent figure standing at $139.5 million for Q1 2026.

• In Q1 2026, Revenue fell 79.07% year-over-year to $139.5 million; the TTM figure through Mar 2026 stood at $532.1 million (down 57.6% YoY), while the FY2025 annual figure was $1.1 billion, up 64.69% from the prior year.
• Revenue for Q1 2026 stood at $139.5 million, down from $147.1 million in the prior quarter.
• The five-year high for Revenue was $734.6 million in Q3 2022, with the low at $70.4 million in Q3 2025.
• The 5-year median for Revenue is $185.9 million (2022), against an average of $285.1 million.
• The sharpest annual moves came in 2023 and 2025: Revenue slumped 88.5% in 2023, then surged 610.3% in 2025.
• Novavax's Revenue stood at $357.4 million in 2022, then declined by 18.48% to $291.3 million in 2023, then sank by 69.69% to $88.3 million in 2024, then jumped by 66.61% to $147.1 million in 2025, then dropped by 5.18% to $139.5 million in 2026.
• Business Quant data shows NVAX's Revenue at $139.5 million in Q1 2026, $147.1 million in Q4 2025, and $70.4 million in Q3 2025.